Gluconorm-G 1 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The combination of these two agents provides complementary mechanisms to achieve better glycemic control in patients inadequately controlled by diet and exercise alone or monotherapy. Gluconorm-G 1 Tablet PR is typically prescribed when metformin alone is insufficient or when a combination therapy is deemed appropriate to optimize glycemic management. The extended-release formulation allows for once-daily dosing, improving patient compliance and minimizing gastrointestinal side effects commonly associated with metformin. It is essential to monitor renal function before and during therapy, as metformin is contraindicated in patients with significant renal impairment. Additionally, caution is advised to avoid hypoglycemia, particularly in the elderly or those with irregular meal patterns. Regular blood glucose monitoring and lifestyle modifications, including diet and exercise, should accompany pharmacotherapy for optimal diabetes management.